New treatments would not be possible without volunteers like you. By joining our community you will get access to clinical trials that are right for you.
Frequently asked questions
A clinical trial is a medical study comparing the effect of different healthcare treatments. They are essential for finding new, safer and more effective treatments for all kinds of health conditions.
Most trials and studies will cover your travel expenses and other expenses you may incur from participation. Some offer additional compensation. Full details of compensation can be found on the relevant study page.
Every clinical trial has unique requirements for taking part, called the ‘inclusion’ and ‘exclusion’ criteria. If you don't qualify for one trial you're interested in, you may qualify for another in your area. You can also fill out your profile here to sign up for alerts from Lindus Health when new trials match your profile.
Yes. The safety of participants is very important. Before any clinical trial can begin, plans must be approved by medical regulators and ethics committees. All participants in clinical trials are under the care of the trial teams, who must include qualified doctors and clinicians. The care they receive must be at least as good as care received by the general population.
Yes, you can still leave a clinical trial at any time, for any reason.
Time commitment varies across clinical trials. Full details of time commitments are available on the study page, or you can ask the study staff.
A ‘control arm’ or ‘placebo’ is often used to fairly assess how effective a treatment is. In some clinical trials, up to half the participants may receive an existing treatment or a placebo (a dummy treatment). The results of these participants are compared against the participants who had the new treatment. This helps remove bias and fairly assess how well the new treatment works.
We ask for your permission before collecting and storing any of your data, and sharing it with the study teams. All results are completely confidential. For full details, please see our privacy policy. Volunteers for clinical trials and studies are essential to moving healthcare forward. If you're ready to get involved, start searching for a trial that matches you today.
.png)
The purpose of this study is to find out if pramipexole is a useful treatment for treatment resistant depression (TRD). A significant proportion of people diagnosed with clinical depression (up to 3 in 10) do not improve with current first-line treatments and are regarded as having TRD. Current medicines for TRD are not particularly effective for many people and often have unwanted effects which may be distressing.
There is some evidence that pramipexole may be an effective treatment for TRD. Pramipexole is unlike current antidepressant drugs in that it acts like a brain chemical called dopamine, which is known to influence people’s motivation to pursue goals and affects how rewarding they find them. This study will require visits to the Campus of Ageing and Vitality, (formerly Newcastle General Hospital), Westgate Road, Newcastle Upon Tyne, NE4 6BE.
Adults with treatment resistant depression
University of Oxford
204
people
March 1, 2024
Tinnitus therapy, including Cognitive Behavioural Therapy (CBT) is an effective treatment for helping people to manage tinnitus. This study aims to compare the effectiveness of a new digital tinnitus therapy, The Oto Tinnitus Programme, to conventional tinnitus therapy.
The Oto Tinnitus Programme is a digital approach to tinnitus management that delivers therapies through a self-paced smartphone app.
The DEFINE study will randomly assign adults with tinnitus to receive the Oto programme or therapist-delivered conventional tinnitus therapy, evaluating both their effectiveness in reducing tinnitus severity as well as the financial implications of both approaches.
Participants will be required to complete electronic surveys throughout the 12-month study period while receiving therapy for their tinnitus. You will be compensated £40 for your time.
Adults with tinnitus persisting for at least 3 months and severe enough to impact their daily life.
Oto Health
196
people
December 31, 2023
The purpose of this study is to assess the use of the telemedicine platform, Facet, for determining patient satisfaction with inclusion of adjunctive therapy during the care of eczema.
The study is approximately 4 weeks long and is fully remote. During this time, you will use the study product, have weekly follow-up surveys and check-ins with the study team.
You will be compensated up to $150 in the form of an electronic gift card.
Men and Women aged 18 to 64 with mild to moderate eczema and who are currently using the Facet platform
Thirty Madison & Johnson and Johnson (JnJ)
40
people
September 30, 2023
Research has suggested that poor gut health may be involved in problems associated with high blood sugar which, left untreated can lead to the development of Type 2 Diabetes (T2D).
The University of Roehampton is investigating if a natural supplement can help maintain good gut health. The study team are looking for pre-diabetic or overweight adults to take part.
The study involves 4 short visits over a period of 16 weeks at the University of Roehampton.
You will be given a £50 amazon voucher for your time.
Adults who have pre-diabetes or who are overweight
The University of Roehampton
25
people
December 31, 2023
The University of Oxford is looking for healthy volunteers aged 18-55 years, who have recovered from two or more episodes of depression, for a study investigating how a licensed drug (prucalopride) affects thinking and emotion.
The study involves 2 study visits over a period of 1-2 weeks at the Warneford Hospital Site, Oxford.
You will be reimbursed £125 for your time and inconvenience. Reasonable travel expenses will be reimbursed.
Adults who have recovered from depression
The University of Oxford
50
people
December 31, 2023
FLORA is a clinical trial investigating fibre supplements as a treatment for pre-diabetes. It has been shown that dietary fibre consumed in our every day diet can help maintain healthy blood glucose levels.
The FLORA Trial is trying to find out whether a unique powdered fibre mix helps maintain healthy blood sugar levels in people with pre-diabetes, where high blood sugar is a risk of diabetes.
The FLORA study is 24 weeks long and involves 3 in-person central clinical visits (these can be done on a weekend). The rest of the study will be conducted remotely, using a smartphone or computer. You will receive £75 for taking part.
People diagnosed with pre-diabetes in the past year
Myota
60
people
April 1, 2023
This study is researching how antidepressants and behavioural therapy affect people who are experiencing low mood. The study hopes to develop better personalised treatment for low mood.
The study is looking for people who are feeling low in mood but who are not currently taking any medication to treat depression or receiving any type of psychological therapy. The study will involve 6 research visits, 1 in person at the research site at the University of Oxford and 5 online. You will receive £150 for participation.
Adults with low mood, who are not currently receiving any medication or therapy.
University of Oxford
135
people
December 30, 2023
The purpose of this study is to find out if pramipexole is a useful treatment for treatment resistant depression (TRD). A significant proportion of people diagnosed with clinical depression (up to 3 in 10) do not improve with current first-line treatments and are regarded as having TRD. Current medicines for TRD are not particularly effective for many people and often have unwanted effects which may be distressing.
There is some evidence that pramipexole may be an effective treatment for TRD. Pramipexole is unlike current antidepressant drugs in that it acts like a brain chemical called dopamine, which is known to influence people’s motivation to pursue goals and affects how rewarding they find them. This study will require visits to Oxford.
Adults with treatment resistant depression
University of Oxford
204
people
March 1, 2024
